来源:药渡撰文:Pharmadeep编辑:维他命10月30日晚间,礼来披露了2025年第三季度财报。数据显示,其旗下代谢治疗药物替尔泊肽(包括降糖版Mounjaro和减重版Zepbound)单季度销售额突破101亿美元,前三季度累计销售额达到248.37亿美元,正式超越默沙东帕博利珠单抗(Keytruda),成为全球新任“药王”。这一更迭比市场预期提前了至少一年,不仅标志着单个药物的商业成功,更...
Source Link来源:药渡撰文:Pharmadeep编辑:维他命10月30日晚间,礼来披露了2025年第三季度财报。数据显示,其旗下代谢治疗药物替尔泊肽(包括降糖版Mounjaro和减重版Zepbound)单季度销售额突破101亿美元,前三季度累计销售额达到248.37亿美元,正式超越默沙东帕博利珠单抗(Keytruda),成为全球新任“药王”。这一更迭比市场预期提前了至少一年,不仅标志着单个药物的商业成功,更...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.